AAPG: ascentage.com Price/Earnings to Growth Multiple
The success of Ascentage Pharma Group (AAPG) is based on the commercialization of oncology drugs and regulatory approvals. The change in the PEG ratio visualizes this dependency, where the 0.00 mark serves as the current indicator of fundamental value. In the future, revenue will rely on the sales of targeted therapies, while research stability will be ensured by strictly calibrated cross-border logistics for biosamples.
Analytical breakdowns for Ascentage Pharma Group (AAPG)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
AAPG - Company Net Income|Net Profit Forecast Ascentage Pharma Group|AAPG - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Ascentage Pharma Corp|AAPG - PEG Multiple|EV/EBITDA Multiple Ascentage|AAPG - Operating profit EBITDA|Net earnings per share for the trailing year Ascentage Pharma|AAPG - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months ascentage.com|AAPG - Net earnings per share growth this year|Expected earnings per share trend next year Ascentage Pharma Group
Fundamental company analysis:AAPG, Ascentage Pharma Group International
Ascentage Pharma Group (AAPG) development of new oncology drugs involves high capital expenditures and uncertainty regarding clinical outcomes. The PEG ratio compares the stock's market value with earnings growth rates, identifying business undervaluation when the value is below one, which is critical for assessing the company's growth potential amid fierce competition in the biopharmaceutical sector.
Competing companies
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|CGON: Price/Earnings to Growth Multiple|URGN - PEG Multiple|Bicara Therapeutics (BCAX) - Price/Earnings to Growth Ratio|Personalis Inc - Growth-Adjusted Payback Ratio|ERAS (Erasca Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Delcath Corp DCTH|PEG Multiple YMAB|PEG Multiple aurabiosciences.com (AURA)|Price/Earnings to Growth Ratio Candel Therapeutics, Inc. CADL|Growth-Adjusted Market Cap to Net Income Accuray Inc (ARAY)|SELLAS Life Sciences Group Inc. - PEG Multiple|Actuate Therapeutics Inc (ACTU) - Price/Earnings to Growth Multiple|CTOR: PEG Multiple|Price to Earnings Adjusted for Growth Rate TuHURA Biosciences (HURA)|Price/Earnings to Growth Ratio Protara Therapeutics, Inc.|Growth-Adjusted P/E Ratio FATE (Fate Therapeutics Inc)|Price/Earnings to Growth Multiple WHWK (Aadi Bioscience Inc)|Company Value to Earnings Growth Ratio TCRX|PEG Multiple CSBR (Champions Oncology, Inc.)|PEG Multiple XBiotech Inc XBIT|CEL-SCI Corp - PEG Multiple|Price to Net Income Growth Ratio OS Therapies Inc. (OSTX)|RADX: PEG Multiple|Price to Earnings Adjusted for Growth Rate Artiva Biotherapeutics (ARTV)|Price/Earnings to Growth Multiple ANL|VERU: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Tempest Therapeutics, Inc. (TPST)|XLO: Market Cap to Earnings and Growth Ratio|PEG Multiple RENB (Renovaro)|Growth-Adjusted Payback Ratio MURA|Kairos Pharma Inc - PEG Multiple|OKUR - PEG Multiple|w2.cytomed.sg (GDTC) - Price/Earnings to Growth Ratio|Curis - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Apollomics Inc.|Price/Earnings to Growth Multiple Tharimmune Corporation (THAR)|PEG Multiple ADVB|PEG Multiple genprex.com (GNPX)|Calidi Biotherapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio SBFM|Xenetic Bio - PEG Multiple|Price to Net Income Growth Ratio Salarius Pharma (SLRX)|Purple Biotech (PPBT) - Price/Earnings to Growth Ratio|American Oncology Network, Inc. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio BeiGene|Price to Earnings Adjusted for Growth Rate Checkpoint Therapeutics Inc. CKPT|Price/Earnings to Growth Multiple ELEV (Elevation Oncology, Inc.)|PEG Multiple icadmed.com (ICAD)|Price/Earnings to Growth Ratio Ikena Oncology IKNA|NTBL (notablelabs.com) - Market Cap to Earnings and Growth Ratio|Viracta - PEG Multiple|MOR - PEG Multiple|NAYA: PEG Multiple|Ascentage (AAPGV) - PEG Multiple
